#### NARINE JEENARINE

Form 4 April 30, 2013

## FORM 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

**OMB** 3235-0287

**OMB APPROVAL** 

Number:

Expires:

January 31,

2005

0.5

Estimated average

burden hours per response...

if no longer subject to Section 16. Form 4 or Form 5 obligations

may continue.

See Instruction

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Last)

(Print or Type Responses)

1. Name and Address of Reporting Person \* NARINE JEENARINE

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to

Issuer

Symbol

ELITE PHARMACEUTICALS INC /NV/ [eltp]

(Check all applicable)

3. Date of Earliest Transaction

\_X\_\_ Director

\_X\_\_ 10% Owner

(Middle)

(Month/Day/Year) 04/25/2013

Officer (give title below)

\_ Other (specify

C/O EPIC PHARMA, LLC, 227-15 NORTH CONDUIT AVENUE

(First)

(Street) 4. If Amendment, Date Original

Applicable Line)

Filed(Month/Day/Year)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

6. Individual or Joint/Group Filing(Check

LAURELTON, NY 11413

(City)	(State)	(Zip) Ta	ble I - Non	-Derivative Sec	curitie	s Acquired	, Disposed of, or	Beneficially	Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)	(I) (Instr. 4)	
Common Stock	04/25/2013		D	150,000	D	\$ 0.08	16,412,461 (2)	I (1)	see footnote
Common Stock	04/26/2013		D	243,926	D	\$ 0.0802	16,168,535 (3)	I (1)	see footnote
Common Stock	04/26/2013		C <u>(7)</u>	8,230,453	A	\$ 0 (7)	24,398,988 (4)	I (1)	see footnote
Common	04/29/2013		D	130,000	D	\$ 0.08	24,268,988	I (1)	see

### Edgar Filing: NARINE JEENARINE - Form 4

Stock						(5)		footnote $\underline{(1)}$
Common Stock	04/29/2013	J <u>(8)</u>	13,367,481	D	\$ 0.0369	15,357,334 (6)	I (1)	see footnote

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	Securiti (A) or I (D)		lof		7. Title and Am Underlying Sec (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	A N S
Series E Convertible Preferred Stock	\$ 0.0243	04/26/2013		С		200	04/26/2013	<u>(10)</u>	Common Stock	
Warrants	\$ 0.0625	04/26/2013		J <u>(9)</u>	1	3,272,999	10/30/2009	10/30/2016	Common Stock	1

# **Reporting Owners**

Reporting Owner Name / Address	Relationships						
reporting o mile remine, reminess	Director	10% Owner	Officer	Other			
NARINE JEENARINE C/O EPIC PHARMA, LLC 227-15 NORTH CONDUIT AVENUE LAURELTON, NY 11413	X	X					

# **Signatures**

Jeenarine Narine 04/29/2013

\*\*Signature of Person

Date

Reporting Owners 2

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Jeenarine Narine is an equity owner and executive officer of each of Epic Pharma, LLC ("EP"), and Epic Investments, LLC ("EI")
- (1) (which is controlled by EP), which owns securities convertible into or exercisable for in excess of 10% of the outstanding shares of common stock of the issuer, and also serves as a director of the issuer.
- Of the 16,412,461 shares of common stock, 14,910,666 shares of common stock are owned indirectly through EI and 1,501,795 shares are owned directly by the reporting person.
- (3) Of the 16,168,535 shares of common stock, 14,666,740 shares of common stock are owned indirectly through EI and 1,501,795 shares are owned directly by the reporting person
- (4) Of the 24,398,988 shares of common stock, 22,897,193 shares of common stock are owned indirectly through EI and 1,501,795 shares are owned directly by the reporting person
- Of the 24,268,988 shares of common stock, 22,767,193 shares of common stock are owned indirectly through EI and 1,501,795 shares are owned directly by the reporting person
- Of the 15,357,334 shares of common stock, 9,399,712 shares of common stock are owned indirectly through EI and 1,501,795 shares are owned directly by the reporting person
- (7) Conversion of Series E Preferred Stock of issuer at the rate of approximately 41,152.26 shares of common for each share of such preferred stock.
- (8) Disposition of shares to its members
- (9) Disposition of warrants to its members
- (10) N/A

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.